Drugmaker Roche has gotten emergency use authorisation from the U.S. Food and Drug Administration for its Elecsys IL-6 test to help distinguish serious provocative reaction in patients with affirmed COVID-19, it said on Thursday.

The test can be utilized to help distinguish coronavirus patients who could be at high danger of intubation with mechanical ventilation, helping specialists choose at an opportune time if ventilation could be required, Roche said.

Roche is trying its joint pain sedate Actemra in patients with coronavirus-connected pneumonia, joining other pharmaceutical organizations trying to re-reason existing medications to battle the scourge.

It additionally plans to test if blending hostile to aggravation sedate Actemra with Gilead Sciences Inc's enemy of viral treatment remdesivir works better against extreme COVID-19 pneumonia than remdesivir alone.

The Elecsys IL-6 test would distinguish patients who could be qualified for Actemra, whose business rose about 30% in the primary quarter due generally to the new coronavirus.